MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Cytokinetics Inc

Închisă

SectorSănătate

60.55 0.67

Rezumat

Modificarea prețului

24h

Curent

Minim

59.52

Maxim

61.42

Indicatori cheie

By Trading Economics

Venit

27M

-134M

Vânzări

65M

67M

Marjă de profit

-201.246

Angajați

498

EBITDA

28M

-108M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+34.02% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

2.9B

7.3B

Deschiderea anterioară

59.88

Închiderea anterioară

60.55

Sentimentul știrilor

By Acuity

92%

8%

360 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Cytokinetics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 apr. 2025, 09:30 UTC

Top știri

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

Comparație

Modificare preț

Cytokinetics Inc Așteptări

Obiectiv de preț

By TipRanks

34.02% sus

Prognoză pe 12 luni

Medie 80.64 USD  34.02%

Maxim 120 USD

Minim 41 USD

În baza a 18 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCytokinetics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

18 ratings

15

Cumpărare

3

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

32.3 / 40.43Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

360 / 371 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
help-icon Live chat